Geneoscopy said CMS added its ColoSense stool-based RNA test to the National Coverage Determination for colorectal cancer screening. The update creates a coverage framework that supports future RNA-based assays as preventive screening expands beyond traditional approaches. Geneoscopy reported 93% sensitivity in average-risk patients for colorectal cancer and 45% sensitivity for advanced adenomas, and said it correctly identified stage I cancer in 100% of cases in reported data. The company also highlighted that ColoSense is FDA-approved and aligned with screening guideline intervals. A strategic collaboration with Labcorp is expected to improve access through Labcorp’s nationwide network, tying reimbursement coverage to distribution and scaling of the diagnostic program.